Amicus (FOLD) was downgraded to a Hold Rating at TD Cowen
In a report released today, Ritu Baral from TD Cowen downgraded Amicus to a Hold, with a price target of $14.50.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
According to TipRanks, Baral is a top 100 analyst with an average return of 40.8% and a 55.51% success rate. Baral covers the Healthcare sector, focusing on stocks such as Insmed, Palvella Therapeutics, and Praxis Precision Medicines.
In addition to TD Cowen, Amicus also received a Hold from Cantor Fitzgerald’s Kristen Kluska in a report issued today. However, on December 17, Citi initiated coverage with a Buy rating on Amicus (NASDAQ: FOLD).
Based on Amicus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $169.06 million and a net profit of $17.31 million. In comparison, last year the company earned a revenue of $141.52 million and had a GAAP net loss of $6.73 million
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FOLD in relation to earlier this year. Earlier this month, Bradley Campbell, the President & CEO of FOLD sold 77,926.00 shares for a total of $845,497.10.
Read More on FOLD:
